Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...

Dyne Therapeutics reported six-month and 24-month data from the Phase I/II trial. Image credit: Sheldon Cooper / SOPA Images / LightRocket via Getty Images. Dyne Therapeutics is seeking US accelerated ...

MSD’s T-cell engager, MK-1045, has demonstrated its tolerability and efficacy in a Phase Ib/II study in B-cell acute lymphocytic leukaemia (B-ALL). Image credit: HJBC via Shutterstock.com. MSD said ...

ARCH Ventures-backed Paradigm Health has acquired Roche-owned Flatiron Health’s clinical research business, while closing an oversubscribed $78m Series B financing round to incorporate clinical trials ...

Speaking at CDMI Europe 2025, GlobalData pharma analyst George El-Helou says the use of AI in R&D could help mitigate patent ...

The safety profile of atogepant over the 24-week period aligned with earlier studies of its use in migraine prevention, with no new safety signals observed. Credit: Komsan Loonprom / Shutterstock.com.

The FDA has debuted a framework that is designed to help companies move away from the use of non-human primate preclinical toxicology testing. Image credit: Deniz_Guler via Shutterstock.com. The US ...

Belite Bio’s ophthalmology asset, tinlarebant, could become the first US-approved treatment for STDG1, following the positive results of the Phase III DRAGON study. Image credit: Edgar Martirosyan via ...

The two main players within this field are Novo Nordisk and Eli Lilly. Credit: zimmytws via Shutterstock. GLP-1 development has massively increased over the five years since 2020 and has become a ...

Phesi, a patient-centric clinical data science company serving the global biopharmaceutical industry, won the Innovation award in the 2025 Clinical Trials Arena Excellence Awards. The award recognizes ...

The FDA has introduced a new draft guidance, which aims to expedite and simplify the biosimilar approval process, which commissioner Marty Makary noted could result in “massive cost reductions for ...